Insulins

Share this content:
INSULINS
Preparation Brand Route Onset
(hrs)
Peak
(hrs)
Duration
(hrs)
Source
INJECTABLES
insulin aspart Fiasp2 Rx SC, IV4 0.27–0.33 1.5–2.2 5−7 human

NovoLog2 Rx SC, IV4, CSII ≤0.25 1−3 3−5 human
insulin aspart protamine/
insulin aspart
NovoLog
Mix 70/30
2
Rx SC ≤0.25 2.4 24 human
insulin degludec Tresiba2 Rx SC 1 9 25 human
insulin detemir Levemir2 Rx SC 1 none 24 human
insulin glargine Basaglar3 Rx SC none ≥24 human
Lantus3 Rx SC 1.1 none ≥24 human
Toujeo3 Rx SC 6 24−120 human
insulin glulisine Apidra3 Rx SC, CSII,
 IV4
≤0.25 1 2−4 human
insulin lispro Humalog3 Rx SC, IV4,5, CSII5 ≤0.25 1 3.5−4.5 human
insulin lispro
protamine/
insulin lispro
Humalog 
Mix 75/25
3
Rx SC ≤0.25 0.5−1.5 24 human
Humalog
Mix 50/50
3
Rx SC ≤0.25 1 16 human
insulin injection regular (R) Humulin R
U-100
1
OTC SC, IV4 0.5 2−4 6−8 human
Humulin R
U-500
1
Rx SC 0.5 1.75−4 24 human
Novolin R2 OTC SC, IV4 0.5 2.5−5 8 human
insulin isophane
suspension (NPH)/
regular insulin (R)
Humulin
70/30
1
OTC SC 0.5 2−12 24 human
Novolin
70/30
2
OTC SC 0.5 2−12 24 human
insulin isophane
suspension (NPH)
Humulin N1 OTC SC 1−2 6−12 18−24 human
Novolin N2 OTC SC 1.5 4−12 24 human
ORAL INHALATIONS
insulin Afrezza Rx oral inh 0.2−0.7 2−3 human
NOTES

Key:  CSII = continuous subcutaneous insulin infusion

1Recombinant (using E. coli)

2Recombinant (using S. cerevisiae)

3Recombinant human insulin analogue (using E. coli)

4IV to be used in a clinical setting under proper medical supervision

5IV and CSII administration for Humalog U-100 only.

 

Onset for injectable formulations is always for the SC route. All times are approximate. Maximum effect occurs between hours listed in duration column; actual effect may last longer. Injectable insulins listed are available in a concentration of 100Units/mL; Humulin R, in a concentration of 500Units/mL for SC injection only, is available by prescription from Lilly for insulin resistant patients who are hospitalized or under close medical supervision.

 

Not an inclusive list of medications and/or dosing instructions. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 4/2018)

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters



CME Focus